A Phase Ib/II Single Arm Study of Cabozantinib Plus Dostarlimab in Women With Recurrent Gynecologic Carcinosarcoma
Latest Information Update: 12 May 2025
At a glance
- Drugs Cabozantinib (Primary) ; Dostarlimab (Primary)
- Indications Carcinoma; Endometrial cancer; Gynaecological cancer; Sarcoma; Uterine cancer
- Focus Therapeutic Use
Most Recent Events
- 04 May 2025 Planned End Date changed from 1 Jan 2026 to 1 Apr 2027.
- 04 May 2025 Planned primary completion date changed from 1 Apr 2025 to 1 Apr 2027.
- 28 Nov 2024 Planned End Date changed from 1 Dec 2025 to 1 Jan 2026.